Anti-CGRP Antibody Variable Region Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CGRP antibodies for treating migraine and inflammatory pain have limitations such as difficulty crossing the blood-brain barrier, long half-lives, and potential vasoconstrictive effects, necessitating the development of more effective anti-CGRP antibodies.
Innovation Solution
Development of a specific anti-CGRP antibody or antigen-binding fragment with defined heavy and light chain variable regions, including specific amino acid sequences for HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, to enhance binding specificity and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently available CGRP antibodies are used for treating migraine, then therapeutic effect is achieved, but difficulty in crossing the blood-brain barrier limits effectiveness
Solution Approach 1:
The patent modifies the antibody structure by humanizing the variable regions and optimizing amino acid sequences to improve pharmacokinetic properties while maintaining binding affinity, thereby enhancing blood-brain barrier penetration capability
2Reliability
If currently available CGRP antibodies are used, then migraine treatment is provided, but long half-lives require frequent administration
Solution Approach 1:
The patent optimizes the antibody's amino acid sequence and structural characteristics to modulate its half-life, achieving a balance between sustained therapeutic effect and reduced administration frequency through controlled degradation rates
3Reliability
If currently available CGRP antibodies are used, then pain relief is achieved, but potential vasoconstrictive effects cause adverse reactions
Solution Approach 1:
The patent designs the antibody to specifically target CGRP with high selectivity through optimized complementarity-determining regions, ensuring that therapeutic action is localized to the intended target while minimizing off-target vasoconstrictive effects on other receptors
Solution Approach 2:
The patent converts the potential harmful vasoconstrictive effect into a beneficial selective binding property by engineering the antibody to distinguish between CGRP and structurally similar peptides, thereby achieving pain relief without adverse vascular effects
4Reliability
If monoclonal CGRP antibodies are produced, then strong selectivity and good tolerance are achieved, but large molecular weights and long half-lives present manufacturing challenges
Solution Approach 1:
The patent modifies the antibody's molecular characteristics by humanizing sequences and optimizing structural parameters to reduce molecular weight while preserving selectivity, and by engineering half-life properties to align with optimal therapeutic windows
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new anti-CGRP antibody effectively binds to CGRP, potentially offering improved therapeutic outcomes for migraine and inflammatory pain while minimizing adverse effects.
Implementation Method 1
an anti-CGRP antibody or an antigen-binding fragment thereof, comprising an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
Provided are an antibody specifically binding to CGRP or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen-binding fragment thereof, and therapeutic and diagnostic methods and use of the antibody or the antigen-binding fragment thereof.